Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Nov 1;202(9):1314-1316.
doi: 10.1164/rccm.202003-0729LE.

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma

Angela M Moran  1 , Sanjay Ramakrishnan  1 , Catherine A Borg  1 , Clare M Connolly  1 , Simon Couillard  1   2 , Christine M Mwasuku  1 , Ian D Pavord  1 , Timothy S C Hinks  1 , Lauri Lehtimӓki  1   3
Affiliations
Comparative Study

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma

Angela M Moran et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Blood eosinophil count (thin transparent lines for individual data, thick lines with markers for geometric group mean, and error bars represent 95% confidence intervals for geometric mean) on logarithmic scale before and after treatment with mepolizumab (100 mg s.c.), benralizumab (30 mg s.c.), or oral prednisolone (30 mg). There was a statistically significant change (P < 0.05 using repeated-measures ANOVA and least significant difference post hoc test) from baseline at 2 and 4 hours in the benralizumab arm, at 4 hours in the prednisolone arm, and from 24 hours onward in the mepolizumab arm. There was no significant difference between the treatment arms at baseline, but the mepolizumab arm differed significantly from benralizumab arm at 2 and 4 hours and 30 days and from prednisolone arm at 4 hours (ANOVA with least significant difference post hoc test).
See this image and copyright information in PMC

Comment in

References

    1. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45–56. - PubMed
    1. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659. - PubMed
    1. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. SIROCCO Study Investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127. - PubMed
    1. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–2458. - PubMed
    1. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197. - PubMed